Pre-exposure prophylaxis vaccination is needed for individuals with occupational risk of Ebola virus exposure, especially for those deploying to areas with Ebola outbreaks. Ervebo® is approved by FDA for prevention of EVD in people 18 years of age and older. Ervebo® is not planned for commercial marketing but is maintained in the Strategic National Stockpile (SNS) with vaccine access within the United States facilitated by the U.S. government. The Centers for Disease Control and Prevention will provide Ervebo® when requested by licensed healthcare providers from institutions or sites with individuals who meet the eligibility criteria included in the 2020 ACIP recommendations.
Licensed healthcare providers interested in Ervebo® for patients that meet the eligibility criteria should send an email to email@example.com with subject line: Request for Ervebo®. The CDC Ebola Vaccine Program will respond with the required instructions and forms for eligible requests.